TELA Bio, Inc. is a commercial stage medical technology company, which focuses on the design, development, and market of tissue reinforcement materials. The company is headquartered in Malvern, Pennsylvania and currently employs 209 full-time employees. The company went IPO on 2019-11-08. The firm is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The firm's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
Follow-Up Questions
TELA Bio Inc의 CEO는 누구입니까?
Mr. Antony Koblish은 2012부터 회사에 합류한 TELA Bio Inc의 Chief Executive Officer입니다.
TELA 주식의 가격 성능은 어떻습니까?
TELA의 현재 가격은 $1.53이며, 전 거래일에 decreased 0% 하였습니다.
TELA Bio Inc의 주요 사업 주제나 업종은 무엇입니까?
TELA Bio Inc은 Health Care 업종에 속하며, 해당 부문은 Health Care입니다
TELA Bio Inc의 시가총액은 얼마입니까?
TELA Bio Inc의 현재 시가총액은 $60.6M입니다
TELA Bio Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 7명의 분석가가 TELA Bio Inc에 대한 분석 평가를 실시했으며, 이는 3명의 강력한 매수, 6명의 매수, 2명의 보유, 0명의 매도, 그리고 3명의 강력한 매도를 포함합니다